Rousselot to unveil gelatin prototypes for innovative medical device development at COMPAMED 2025

Rousselot, Darling Ingredients' premier collagen and gelatin brand, will participate in COMPAMED 2025, November 17-20, 2025, in Düsseldorf, Hall 8, Booth AK14.

Rousselot will demonstrate the unique advantages of using gelatin as a high-performance biomaterial for medical devices. Attendees will have the chance to engage directly with Rousselot's experts and explore application-driven prototypes - including hemostats, dermal fillers, and microneedles - designed to accelerate formulation development and reduce time to market.

Highlights on display will include:

• Gelatin-based films and foams designed for use in hemostatic sponges or anti-adhesion films, offering targeted performance and excellent handling properties for development
• Flowable hemostats with customizable viscosity, bio resorption and hemostatic efficiency to meet device requirements.
• Dermal fillers where gelatin enables customized rheology, injectability, and biocompatibility
• Microneedle prototypes showcasing gelatin's ability to help optimize mechanical strength, dissolution rates, and active ingredient delivery

Gelatin is a trusted biomaterial for developers of advanced medical technologies, valued for its physicochemical properties and proven biocompatibility. Rousselot's extensive portfolio of modified and non-modified gelatins is known for its high purity, consistent quality and comprehensive regulatory documentation. These attributes help medical device manufacturers reduce variability in preclinical and clinical development, supporting fast track to market.

Rousselot invites attendees to schedule a meeting with its technical and regulatory teams to explore standard and customized solutions for medical device development.